低分子肝素治疗AECOPD患者对内皮舒缩因子的影响

Effect of low molecular weight heparin on endothelial compression factor in AECOPD patients

目的研究低分子肝素治疗AECOPD患者的临床疗效及对内皮舒缩因子的影响。方法将本院收治的67例AECOPD患者随机分成实验组35例,对照组32例,收集健康体检患者33例为健康组;给予对照组常规治疗方案,实验组在常规治疗的基础上加用低分子肝素治疗;记录并比较实验组与对照组治疗前后的肺功能FEV1%、FEV1/FVC%数据,抽取各组静脉血检测内皮素-1(ET-1)、前列环素(PGI2)及D-dimer的血清水平及治疗前后差异。结果实验组与对照组治疗后肺功能明显改善;实验组与对照组治疗前血清ET-1、D-dimer水平较健康组明显升高;实验组与对照组治疗后血清ET-1、D-dimer水平有所下降,且实验组下降水平更显著;实验组与对照组治疗前血清PGI2水平较健康组明显降低,经治疗后血清PGI2水平有所升高,且实验组升高水平更显著,差异有统计学意义(P <0. 01)。结论对AECOPD使用低分子肝素治疗有助于改善肺功能及血管内皮舒缩功能,有较好的临床疗效。

Objective To study the clinical effect of low molecular weight heparin on AECOPD and its effect on endothelium contraction factor. Methods 67 AECOPD patients were randomly divided into the experimental group （35 cases） and the control group （32 cases）. Another 33 healthy people were taken as the healthy control group. The control group received routine treatment. The experimental group was given routine treatment and low molecular weight heparin. The value of FEV1% and FEV1/FVC% of pulmonary function were recorded and compared between the experimental group and the control group before and after treatment. The levels of endothelin-1 （ ET-1 ） , prostacyclin （ PGI2 ） and D-dimer were also recorded. Results Their lung function improved significantly after treatment in both groups. The levels of ET-1 and D-dimer in the experimental group and the control group before treatment were significantly higher than those in the healthy control group. The levels of ET-1, D-dimer in the experimental group and the control group was significantly lower after treatment. The level of PGI2 in the experimental group and the control group before treatment was significantly lower than that in the healthy control group. After treatment, serum PGI2 level increased and the level of the experimental group increased more significantly （ P 〈 0. 01 ）. Conclusion Low molecular weight heparin can improve pulmonary function and vascular endothelium systolic and contractile function in treatment of AECOPD patients, and it has good clinical efficacy.